Why does Goldman Sachs think the market is wrong on Intuitive Surgical?

Analysts believe concerns are overblown and the company remains dominant in surgical robotics with strong demand.

How much has Intuitive Surgical stock fallen in the past year?

The stock has fallen over 20% in the past year.

Goldman Sachs Says Crowd Is Wrong on Beaten-Down Intuitive Surgical

Goldman Sachs upgraded Intuitive Surgical (ISRG) to Buy, challenging the market's negative view on the beaten-down medical robotics giant.

July 15, 2026

1 min read

Source: Motley Fool

Goldman Sachs has upgraded Intuitive Surgical (ISRG) to a Buy rating, pushing back against the bearish consensus on the medical robotics leader whose stock has declined sharply.

Rating Change

Previous Rating: Neutral
New Rating: Buy
New Price Target: Not disclosed

Analyst Rationale

Goldman Sachs analysts believe the market's concerns are overblown, citing Intuitive's strong competitive moat in robotic surgery, resilient demand for its da Vinci systems, and expansion into new procedures and emerging markets.

Context

ISRG shares have fallen over 20% in the past year amid worries about hospital capital spending and rising competition. However, Intuitive remains the dominant player in surgical robotics with a vast installed base.

What to Make of It

Goldman's contrarian call suggests the sell-off may be overdone. Investors should weigh the company's fundamentals and risks before making decisions.

Frequently Asked Questions

Goldman Sachs upgraded the stock to 'Buy' from 'Neutral'.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.